UBS Cuts 10x Genomics Price Target to $61 From $90 per Share
UBS lowered its price target on 10x Genomics (TXG) to $61 per share from $90, according to Dow Jones Newswires, which cited Benzinga ratings data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
UBS has reduced its price target for 10x Genomics shares to $61 per share from $90, Dow Jones Newswires reported. The report also pointed to Benzinga's analyst ratings page, which tracks recent rating decisions on TXG stock.
why it matters
A cut in a price target reflects an analyst's revised valuation of the stock and usually concerns one company only. Such changes have little effect on the broader market, but investors often weigh them when assessing TXG and peers in the life sciences sector.
tags
instruments
sources
- 10x Genomics Price Target Cut to $61.00/Share From $90.00 by UBS — Dow Jones Newswires, 6 November 2026 at 23:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗